Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Burman

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Plos Medicine|September 16, 2009
Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysisDick Menzies, Andrea Benedetti, Anita Paydar, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2007
Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacinMarc Weiner, William Burman, Chi-Cheng Luo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 5, 2008
Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trialWilliam Burman, Birgit Grund, Jacqueline Neuhaus, et al.
Antimicrobial Agents and Chemotherapy|March 12, 2014
Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailabilityRadojka M Savic, Yanhui Lu, Erin Bliven-Sizemore, et al.
American Journal of Respiratory and Critical Care Medicine|January 18, 2003
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentineMarc Weiner, William Burman, Andrew Vernon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 22, 2005
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosisMarc Weiner, Debra Benator, William Burman, et al.
American Journal of Respiratory and Critical Care Medicine|August 20, 2005
Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosisWilliam Burman, Debra Benator, Andrew Vernon, et al.
Journal of Clinical Microbiology|October 8, 2010
Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trialsMarc Weiner, Thomas J Prihoda, William Burman, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2010
Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrationsMarc Weiner, Charles Peloquin, William Burman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2008
High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patientsMichael Saag, Rukmini Balu, Elizabeth Phillips, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Plos Medicine|September 16, 2009
Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysisDick Menzies, Andrea Benedetti, Anita Paydar, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2007
Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacinMarc Weiner, William Burman, Chi-Cheng Luo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 5, 2008
Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trialWilliam Burman, Birgit Grund, Jacqueline Neuhaus, et al.
Antimicrobial Agents and Chemotherapy|March 12, 2014
Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailabilityRadojka M Savic, Yanhui Lu, Erin Bliven-Sizemore, et al.
American Journal of Respiratory and Critical Care Medicine|January 18, 2003
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentineMarc Weiner, William Burman, Andrew Vernon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 22, 2005
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosisMarc Weiner, Debra Benator, William Burman, et al.
American Journal of Respiratory and Critical Care Medicine|August 20, 2005
Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosisWilliam Burman, Debra Benator, Andrew Vernon, et al.
Journal of Clinical Microbiology|October 8, 2010
Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trialsMarc Weiner, Thomas J Prihoda, William Burman, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2010
Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrationsMarc Weiner, Charles Peloquin, William Burman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2008
High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patientsMichael Saag, Rukmini Balu, Elizabeth Phillips, et al.
Pageof 4